https://www.aigom.it/wp-content/uploads/2024/07/ART23.7.png1256960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-22 08:42:442024-07-22 08:54:30ADJUVANT TRASTUZUMAB EMTANSINE VERSUS PACLITAXEL PLUS TRASTUZUMAB FOR STAGE I HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER: 5-YEAR RESULTS AND CORRELATIVE ANALYSES FROM ATEMPT
https://www.aigom.it/wp-content/uploads/2024/07/ART16.7.LOC_.png1272960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-15 07:09:222024-07-15 07:09:22CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2024/07/ART09.07.png1172960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 07:46:032024-07-09 07:55:25OVERALL SURVIVAL IN PATIENTS WITH ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE RANDOMIZED ENGOT-EN6/GOG-3031/RUBY TRIAL.
https://www.aigom.it/wp-content/uploads/2024/07/ART.02.07.png1211960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-01 07:11:442024-07-01 07:35:08LORLATINIB VERSUS CRIZOTINIB IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: 5-YEAR OUTCOMES FROM THE PHASE III CROWN STUDY
https://www.aigom.it/wp-content/uploads/2024/06/ART.25.6.png1205950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-24 07:06:202024-06-24 07:06:20OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2024/06/ART18.6.png1080935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-18 09:01:252024-06-18 09:01:25IMPROVED CLINICAL STAGING SYSTEM FOR LOCALIZED PANCREATIC CANCER USING THE ABC FACTORS: A TAPS CONSORTIUM STUDY
https://www.aigom.it/wp-content/uploads/2024/06/ART11.06.png1257935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-10 08:38:262024-06-10 08:38:26TRASTUZUMAB PLUS GEMCITABINE-CISPLATIN FOR TREATMENT-NAïVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BILIARY TRACT ADENOCARCINOMA: A MULTICENTER, OPEN-LABEL, PHASE II STUDY (TAB)
https://www.aigom.it/wp-content/uploads/2024/06/ART.04.06.png1137935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-06-03 08:24:502024-06-03 08:24:50PERIOPERATIVE DURVALUMAB FOR RESECTABLE NON-SMALL-CELL LUNG CANCER
https://www.aigom.it/wp-content/uploads/2024/05/ESMOART28.5.png1112935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-23 07:33:562024-05-27 07:38:05REGOMA-OSS: A LARGE, ITALIAN, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF REGORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
https://www.aigom.it/wp-content/uploads/2024/05/art.21.5.png1063935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-17 09:32:042024-05-17 09:32:04FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
